Which has higher valuation & earnings, NBTX or FDMT?

Nanobiotix has higher earnings, but lower revenue than 4D Molecular Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $29.64M 62.73 -$27.11M N/A N/A 4D Molecular Therapeutics $85.21M 7.12 -$140.11M -$2.57 N/A

4D Molecular Therapeutics (FDMT) Competitors

$11.60 +1.18 (+11.32%)

Closing price 04:00 PM Eastern

Extended Trading

$11.78 +0.19 (+1.59%)

As of 07:50 PM Eastern

Compare

FDMT vs. RAPP, IOVA, NBTX, MESO, and NRIX

Should you buy 4D Molecular Therapeutics stock or one of its competitors? MarketBeat compares 4D Molecular Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4D Molecular Therapeutics include Rapport Therapeutics (RAPP), Iovance Biotherapeutics (IOVA), Nanobiotix (NBTX), Mesoblast (MESO), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

How does 4D Molecular Therapeutics compare to Rapport Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

4D Molecular Therapeutics currently has a consensus price target of $29.88, suggesting a potential upside of 157.54%. Rapport Therapeutics has a consensus price target of $58.83, suggesting a potential upside of 51.32%. Given 4D Molecular Therapeutics' higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Rapport Therapeutics had 3 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 4 mentions for Rapport Therapeutics and 1 mentions for 4D Molecular Therapeutics. Rapport Therapeutics' average media sentiment score of 1.62 beat 4D Molecular Therapeutics' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
4D Molecular Therapeutics	Neutral
Rapport Therapeutics	Very Positive

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Rapport Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	7.12	-$140.11M	-$2.57	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Rapport Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Rapport Therapeutics' return on equity of -24.78% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Rapport Therapeutics beats 4D Molecular Therapeutics on 10 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Iovance Biotherapeutics has a net margin of -123.92% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

4D Molecular Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$285.61M	6.94	-$390.98M	-$0.95	N/A
4D Molecular Therapeutics	$85.21M	7.12	-$140.11M	-$2.57	N/A

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Iovance Biotherapeutics had 4 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for Iovance Biotherapeutics and 1 mentions for 4D Molecular Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.50 beat 4D Molecular Therapeutics' score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Iovance Biotherapeutics	Neutral
4D Molecular Therapeutics	Neutral

Iovance Biotherapeutics currently has a consensus price target of $8.43, indicating a potential upside of 89.83%. 4D Molecular Therapeutics has a consensus price target of $29.88, indicating a potential upside of 157.54%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Iovance Biotherapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market.

Summary

4D Molecular Therapeutics beats Iovance Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Nanobiotix has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Nanobiotix's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Nanobiotix has higher earnings, but lower revenue than 4D Molecular Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64M	62.73	-$27.11M	N/A	N/A
4D Molecular Therapeutics	$85.21M	7.12	-$140.11M	-$2.57	N/A

In the previous week, Nanobiotix and Nanobiotix both had 1 articles in the media. Nanobiotix's average media sentiment score of 0.00 equaled 4D Molecular Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nanobiotix	Neutral
4D Molecular Therapeutics	Neutral

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nanobiotix has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market.

Nanobiotix presently has a consensus target price of $37.33, indicating a potential upside of 2.00%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 157.54%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

4D Molecular Therapeutics beats Nanobiotix on 7 of the 12 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Mesoblast?

4D Molecular Therapeutics (NASDAQ:FDMT) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Mesoblast has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Mesoblast's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Mesoblast	N/A	N/A	N/A

In the previous week, 4D Molecular Therapeutics and 4D Molecular Therapeutics both had 1 articles in the media. Mesoblast's average media sentiment score of 0.34 beat 4D Molecular Therapeutics' score of 0.00 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Overall Sentiment
4D Molecular Therapeutics	Neutral
Mesoblast	Neutral

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mesoblast has lower revenue, but higher earnings than 4D Molecular Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	7.12	-$140.11M	-$2.57	N/A
Mesoblast	$65.38M	30.45	-$102.14M	-$0.54	N/A

4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

4D Molecular Therapeutics presently has a consensus price target of $29.88, suggesting a potential upside of 157.54%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Mesoblast beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Nurix Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

4D Molecular Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

In the previous week, Nurix Therapeutics had 8 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 9 mentions for Nurix Therapeutics and 1 mentions for 4D Molecular Therapeutics. Nurix Therapeutics' average media sentiment score of 1.11 beat 4D Molecular Therapeutics' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
4D Molecular Therapeutics	Neutral
Nurix Therapeutics	Positive

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

4D Molecular Therapeutics currently has a consensus price target of $29.88, indicating a potential upside of 157.54%. Nurix Therapeutics has a consensus price target of $32.20, indicating a potential upside of 70.73%. Given 4D Molecular Therapeutics' higher probable upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

4D Molecular Therapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	7.12	-$140.11M	-$2.57	N/A
Nurix Therapeutics	$71.78M	27.17	-$264.46M	-$3.16	N/A

4D Molecular Therapeutics has a net margin of -182.34% compared to Nurix Therapeutics' net margin of -411.37%. 4D Molecular Therapeutics' return on equity of -36.83% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Summary

4D Molecular Therapeutics beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$606.45M	$2.97B	$6.46B	$12.11B
Dividend Yield	N/A	1.78%	2.68%	5.81%
P/E Ratio	-4.51	18.43	24.71	24.00
Price / Sales	7.12	345.21	492.47	90.40
Price / Cash	N/A	55.91	27.92	37.84
Price / Book	1.31	4.11	10.82	6.53
Net Income	-$140.11M	$64.45M	$3.56B	$336.99M
7 Day Performance	33.79%	2.24%	1.67%	-0.22%
1 Month Performance	34.88%	1.04%	0.43%	0.77%
1 Year Performance	207.69%	30.05%	32.84%	31.57%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	1.5488 of 5 stars	$11.60 +11.3%	$29.88 +157.5%	+152.3%	$544.72M	$85.21M	N/A	120	News Coverage Insider Trade High Trading Volume
RAPP Rapport Therapeutics	3.0657 of 5 stars	$38.26 -0.4%	$58.83 +53.8%	+249.7%	$1.84B	N/A	N/A	N/A	Positive News
IOVA Iovance Biotherapeutics	2.4631 of 5 stars	$4.03 -1.2%	$8.43 +109.1%	+105.1%	$1.82B	$263.50M	N/A	500
NBTX Nanobiotix	2.5056 of 5 stars	$37.12 +4.4%	$37.33 +0.6%	+688.1%	$1.81B	$36.87M	N/A	100	Gap Down High Trading Volume
MESO Mesoblast	1.2521 of 5 stars	$13.76 -1.2%	N/A	+48.5%	$1.80B	$17.20M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. RAPP, IOVA, NBTX, MESO, and NRIX

How does 4D Molecular Therapeutics compare to Rapport Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Iovance Biotherapeutics?

Summary

How does 4D Molecular Therapeutics compare to Nanobiotix?

Summary

How does 4D Molecular Therapeutics compare to Mesoblast?

Summary

How does 4D Molecular Therapeutics compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. RAPP, IOVA, NBTX, MESO, and NRIX

How does 4D Molecular Therapeutics compare to Rapport Therapeutics?

Do analysts prefer FDMT or RAPP?

Does the media refer more to FDMT or RAPP?

Do institutionals & insiders hold more shares of FDMT or RAPP?

Which has more risk and volatility, FDMT or RAPP?

Which has higher valuation & earnings, FDMT or RAPP?

Is FDMT or RAPP more profitable?

Summary

How does 4D Molecular Therapeutics compare to Iovance Biotherapeutics?

Is IOVA or FDMT more profitable?

Which has better valuation & earnings, IOVA or FDMT?

Do institutionals and insiders have more ownership in IOVA or FDMT?

Does the media favor IOVA or FDMT?

Do analysts prefer IOVA or FDMT?

Which has more risk & volatility, IOVA or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Nanobiotix?

Is NBTX or FDMT more profitable?

Which has higher valuation & earnings, NBTX or FDMT?

Does the media refer more to NBTX or FDMT?

Do institutionals and insiders have more ownership in NBTX or FDMT?

Which has more volatility & risk, NBTX or FDMT?

Do analysts prefer NBTX or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Mesoblast?

Is FDMT or MESO more profitable?

Does the media prefer FDMT or MESO?

Do insiders & institutionals believe in FDMT or MESO?

Which has higher earnings & valuation, FDMT or MESO?

Which has more risk and volatility, FDMT or MESO?

Do analysts recommend FDMT or MESO?

Summary

How does 4D Molecular Therapeutics compare to Nurix Therapeutics?

Which has more risk and volatility, FDMT or NRIX?

Does the media refer more to FDMT or NRIX?

Do institutionals and insiders have more ownership in FDMT or NRIX?

Do analysts recommend FDMT or NRIX?

Which has preferable earnings & valuation, FDMT or NRIX?

Is FDMT or NRIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools